<DOC>
	<DOCNO>NCT02279875</DOCNO>
	<brief_summary>The purpose study evaluate mycobactericidal activity , safety , tolerability , pharmacokinetics 6 dos linezolid : 300 mg per day , 300 mg twice per day , 600 mg per day , 600 mg twice per day 1200 mg per day administer orally 14 consecutive day 1200 mg administer three time per week two week adult subject newly diagnose drug‐sensitive , smear‐positive pulmonary tuberculosis .</brief_summary>
	<brief_title>A Phase 2 Trial Evaluate Efficacy Safety Linezolid Tuberculosis Patients . ( LIN-CL001 )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>Subjects require meet follow inclusion criterion order randomize . 1 . Provide write , informed consent prior trial‐related procedure . 2 . Male female , age 18 75 year inclusive . 3 . Body weight ( light clothing shoe ) 35 100 kg , inclusive . 4 . Drug‐sensitive pulmonary Tuberculosis ( TB ) determine test trial appoint laboratory : M.tb positive rifampicin sensitive molecular test ( e.g . GeneXpert Hain ) sputum smear‐positive pulmonary TB direct microscopy acid‐fast bacillus ( least 1+ IUATLD/WHO scale ) . 1. either newly diagnose OR 2. untreated least 3 year cure previous episode ( Subject give history cure previous treatment ) ; AND 3 . Previous TB treatment must discontinue per exclusion criterion 17 . 5 . A chest X‐Ray opinion Investigator consistent TB . 6 . Ability produce adequate volume sputum estimate screen Coached Spot Sputum Sample assessment ( estimate 10 ml overnight production ) . 7 . Be non‐childbearing potential use effective method birth control , define : Non‐childbearing potential : 1 . Subject ‐ heterosexually active practice sexual abstinence ; OR 2 . Female Subject/sexual partner ‐ bilateral oophorectomy , bilateral tubal ligation and/or hysterectomy postmenopausal history menses least 12 consecutive month ; OR 3 . Male Subject/sexual partner ‐ vasectomise bilateral orchidectomy minimally three month prior screen ; Effective birth control method : A double contraceptive method use follow : 1 . Double barrier method include 2 follow : male condom , diaphragm , cervical cap , female condom ( male female condom use together ) ; OR 2 . Barrier method ( one ) combine hormone‐based contraceptive intra‐uterine device female Subject/partner ; AND 3 . Are willing continue practice one mentioned birth control method throughout treatment 1 month ( male female Subjects ) last dose study medication discontinuation study medication case premature discontinuation . Subjects exclude participation meet follow criterion . Medical Criteria 1 . Evidence clinically significant ( judged Investigator ) , metabolic , gastrointestinal , cardiovascular , musculoskeletal , ophthalmological , pulmonary , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) include malaria . A rapid test malaria may carry indicated . 2 . Poor general condition delay treatment tolerate per discretion Investigator . 3 . Clinically significant evidence extrathoracic TB ( e.g . miliary TB , abdominal TB , urogenital TB , osteoarthritic TB , TB meningitis ) , judge Investigator . 4 . History allergy hypersensitivity study Investigational Medicinal Products related substance . 5 . Known suspected current alcohol and/or drug abuse ( positive urine drug screen ) history thereof within past 2 year , opinion Investigator , sufficient compromise safety and/or cooperation Subject . 6 . A history seizures risk factor seizure . 7 . For HIV infected Subjects : 1. CD4+ count &lt; 250 cells/μL ; 2. AIDS‐defining opportunistic infection malignancy ( except pulmonary TB ) ; 3 . OR received antiretroviral therapy medication within last 90 day 4 . OR receive oral intravenous antifungal medication within last 90 day . 8 . Having participated clinical study/ies investigational agent/s within 8 week prior trial start . 9 . Significant cardiac arrhythmia require medication QT interval ECG &gt; 500msec screening ECG . 10 . Subjects uncontrolled hypertension , pheochromocytoma , thyrotoxicosis 11 . Females pregnant breast‐feeding , plan conceive child study within 1 month cessation treatment 12 . Diabetes Mellitus Specific Treatments 13 . Previously receive treatment linezolid . 14 . Known allergy intolerance linezolid . 15 . Concomitant use monoamine oxidase inhibitor ( MAOIs ) prior use within 1 month screening . 16 . Concomitant use serotonergic agent include SSRI/SNRI antidepressant prior use within 3 day screen avoid possible subject agent linezolid risk serotonin syndrome . 17 . Treatment drug active M.tb within 3 month prior Day 1 ( include limit isoniazid , ethambutol , amikacin , bedaquiline , clofazimine , cycloserine , fluoroquinolones , rifabutin , rifampicin , streptomycin , kanamycin , para‐aminosalicylic acid , rifapentine , pyrazinamide , thioacetazone , capreomycin , thioamides , metronidazole ) . Based Laboratory Abnormalities : 18 . Subjects follow toxicity screen define enhanced Division Microbiology Infectious Disease ( DMID ) adult toxicity table ( November 2007 ) : 1. creatinine grade 2 great [ &gt; 1.5 x Upper Limit Normal ( ULN ) ] ; 2. hemoglobin level &lt; 8.0 gm/dL ; 3. platelet count &lt; 80,000/mm3 ; 4. absolute neutrophil count &lt; 1000/mm3 5. serum potassium , serum magnesium calcium ( correct albumin ) level less low limit normal laboratory ; 6. aspartate aminotransferase ( AST ) grade 3 great ( ≥3.0 x ULN ) exclude ; 7. alanine aminotransferase ( ALT ) grade 3 great ( ≥3.0 x ULN ) exclude ; 8. alkaline phosphatase ( ALP ) grade 4 ( &gt; 8.0 x ULN ) exclude , grade 3 ( ≥3.0 8.0 x ULN ) must discuss approve Sponsor Medical Monitor ; 9. total bilirubin grade 3 great ( ≥2.0 x ULN , ≥1.50 x ULN accompany increase liver function test ) exclude , grade 2 ( ≥1.50 x ULN , ≥1.25 x ULN accompany increase liver function test ) must discuss approve Sponsor Medical Monitor ; Any laboratory value exclude Subject may repeat confirm eligibility . All inclusion exclusion criterion must meet . If single variable/value outside range acceptability , multiple value close limit and/or whenever Investigator reason suspect might health problem ( TB ) , enrollment consider discuss case sponsor medical monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Drug-Sensitive Tuberculosis</keyword>
	<keyword>Linezolid</keyword>
	<keyword>HRZE ( isoniazid , rifampicin , pyrazinamide , ethambutol )</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>